SCHEMBL2413435

SCHEMBL2413435

Cc1ccc2[nH]c(C(=O)NC(c3ccc(C(=O)NO)cc3)C(C)(C)C)c(C)c2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 3/20 0.43
HDAC6 Q9UBN7 3/20 0.43
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
RAB9A P51151 1/20 0.41
NPC1 O15118 1/20 0.40
PDE2A O00408 5/20 0.39
ADORA1 P30542 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
EGFR P00533 1/20 0.38
ALDH1A1 P00352 4/20 0.38
KDM4E B2RXH2 2/20 0.38
HTT P42858 2/20 0.38
LMNA P02545 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HPGD P15428 1/20 0.38
GFER P55789 1/20 0.38
HSD17B10 Q99714 1/20 0.38
GAA P10253 2/20 0.37
MAPT P10636 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2406998 0.80 TP53 (0.50) HDAC1HDAC6RAB9ANPC1PDE2A
SCHEMBL12279807 0.79 HDAC6 (0.61) HDAC1HDAC6MEN1KMT2APDE2A
SCHEMBL2408609 0.78 HDAC1 (0.43) HDAC1HDAC6PDE2AHDAC8
SCHEMBL2409381 0.77 HDAC8 (0.45) HDAC1HDAC6MEN1KMT2ARAB9A
SCHEMBL2408196 0.73 HDAC1 (0.43) HDAC1HDAC6PDE2AHDAC8
SCHEMBL2409463 0.71 HDAC1 (0.67) HDAC1HDAC6HDAC8ALDH1A1LMNA
SCHEMBL2407741 0.70 EGFR (0.52) HDAC1HDAC6RAB9ANPC1EGFR
SCHEMBL12279954 0.70 HDAC1 (0.43) HDAC1HDAC6PDE2AHDAC8
SCHEMBL12279790 0.70 PDE2A (0.47) HDAC1HDAC6PDE2AHDAC8LMNA
SCHEMBL12280557 0.70 HDAC6 (0.54) HDAC1HDAC6HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9382197-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2016-07-05 US claimed
US-9382197-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2016-07-05 US disclosed
US-9382197-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2016-07-05 US disclosed
US-20140275093-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-09-18 US disclosed
US-20140275093-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-09-18 US disclosed
US-20110212969-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-09-01 US disclosed
US-20110212969-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275093-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC10, HDAC1 HDAC1 3/4885HDAC6 1/4885MEN1 3689/4885
US-20110212969-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC10, HDAC1 HDAC1 3/4885HDAC6 1/4885MEN1 3689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.